1.Primary Health Properties plc
PHP.L (LSE)
Primary Health Properties plc stands out as a UK-listed healthcare property REIT that appeals to investors seeking real-asset income-oriented equity exposure. With a noteworthy dividend yield of 7.69%, it has garnered a strong B+ analyst rating, making it a compelling option for those aiming to add reliability to their portfolios. However, investors should note its mixed performance, with a modest 1-year return of 0.26% and a significant decline of 40.54% over the past five years.
Pros:
- High dividend yield
- Focus on healthcare real estate
Cons:
- Significant 5-year return decline
- Market volatility risk
2.Legal & General Group plc
LGEN.L (LSE)
Legal & General Group plc stands out as a top-rated option among UK-listed financial stocks, recently appearing on Fidelity’s “most bought shares in August” list. With an impressive dividend yield of 8.59% and a one-year return of 16.64%, this stock is ideal for investors seeking reliable income and solid performance. Though analysts have given it a C rating, its consistent payouts from a financially healthy company make it a noteworthy consideration for those looking to enhance their portfolios.
Pros:
- High dividend yield
- Strong historical performance over 10 years
Cons:
- Market volatility risk
- Lower growth grade
3.Haleon plc
HLN (NYSE)
Haleon plc stands out as a UK-listed consumer healthcare company, recently appearing on Fidelity's list of "most bought shares," making it a noteworthy choice for investors looking for large-cap defensive exposure. With a dividend yield nearing 2% and a solid 5-year return of over 30%, it offers potential for reliable income alongside growth. Analysts have given Haleon a favorable rating of A- with a 12-month price target of $10.20, indicating confidence in its stability and performance.
Pros:
- Defensive exposure in consumer healthcare
- Strong market presence with notable brands
Cons:
- Lower 1-year return compared to historical performance
- Market volatility risk
Final Words
In August 2026, you should consider Haleon plc as a strong investment option within the UK market, particularly for its defensive appeal in the healthcare sector. Take time to compare this and other options, and conduct your own research to make informed investment decisions.
Frequently Asked Questions
In August 2026, Haleon plc (ticker: HLN) has shown a YTD return of -3.26% and a 1-year return of 0.82%. The stock is currently trading around $9.90 on the NYSE.
Haleon plc offers a dividend yield of approximately 1.96%, with dividends distributed semi-annually. The next dividend is set at $0.1333.
Haleon plc is considered a strong option for investors seeking large-cap defensive exposure, especially in the healthcare sector. Its diverse product portfolio includes well-known brands, making it a stable choice.
Investing in Haleon plc carries typical market risks, including stock volatility and sector-specific risks in healthcare. It's essential to consider the company's performance trends and the overall market environment before investing.
Haleon plc's performance can be compared to other healthcare stocks by analyzing factors like market cap, dividend yield, and historical returns. Investors should review these metrics to determine its standing in the market.
Haleon plc, with a market cap of approximately $43.07 billion, is a significant player in the consumer healthcare sector. The company's established brands and global reach contribute to its robust market position.
